The improving utility of renal transplantation in the management of end-stage renal disease.
The results achieved by treating patients with end-stage renal failure with allotransplantation have improved dramatically since the 1950s when immunosuppression was induced by total body irradiation and there was a lack of HLA typing. Although long-term hemodialysis offers prolonged survival and partial rehabilitation for many individuals with end-stage renal disease, the technique is inconvenient and time consuming. Patients are restricted by necessary proximity to the machine, dietary limitations, potential failure of access sites, and complications of various organ systems. Despite the availability of dialysis and the federal funds to partially pay for treatment, long-term dialysis still remains a costly process for the individual in need of care. During the same period when dialysis techniques improved and became widely available, transplantation of the human kidney became an established and justified treatment for some patients with end-stage renal disease. Those with successful kidney allografts may achieve remarkable recovery and are often able to return to normal lives. One of the more striking improvements in the results of renal transplantation in recent years had been the decline in morbidity and mortality. Mortality by the end of the first year after transplantation during which time most deaths occur, is currently less than 5 percent in a number of major medical units. In part, this decline represents a change in philosophy by transplant teams, who now tend to decrease immunosuppression and sacrifice the kidney rather than the patient in instances of inexorable rejection. In addition, declining mortality is directly attributable to improved methods of preventing, discovering, and treating patients with potential or real infections. More recently, in some centers, the rate of successful engraftment has shown gratifying improvement due to refinements in tissue typing, improved cross matching, new immunosuppressive therapies, and pretransplant conditioning with blood products. These recent improvements are the primary focus of this review. Unfortunately, until very recently, rates of functional survival of allografts have not been satisfactory.
D000293:Adolescent; D000328:Adult; D001161:Arteriosclerosis / Q000209:etiology; D002102:Cadaver; D002648:Child; D002675:Child, Preschool; D005069:Evaluation Studies as Topic; D005921:Glomerulonephritis / Q000209:etiology; D006084:Graft Rejection; D006680:HLA Antigens / Q000032:analysis; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy; D007676:Kidney Failure, Chronic / Q000276:immunology / Q000601:surgery*; D016030:Kidney Transplantation; D008875:Middle Aged; D011183:Postoperative Complications; D011379:Prognosis; D012306:Risk; D018805:Sepsis / Q000209:etiology; D014570:Urologic Diseases / Q000209:etiology
D006680:HLA Antigens